Target
MYC
24 abstracts
Abstract
Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.Org: Memorial Sloan Kettering Cancer Center, University of Bari "A. Moro" and Policlinico Consorziale, Kyushu University, Texas Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea,
Abstract
A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance).Org: Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Duke University Medical Center, Duke University Department of Biostatistics and Bioinformatics,
Abstract
Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3).Org: Division of Blood Disorders, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, Namık Kemal Üniversitesi, Nantes University Hospital, Centre Hospitalier Universitaire (CHU) de Poitiers,
Abstract
Rituximab, chidamide, and zanubrutinib (ZCR) ± CHOP as a regimen for treatment naive (TN) double-expressor DLBCL (DE-DLBCL).Org: Affiliated Dongguan People’s Hospital, Dongguan People’s Hospital,
Abstract
Randomized phase II/III study of R-CHOP +/- venetoclax in previously untreated MYC/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701.Org: Massachusetts General Hospital, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, Mayo Clinic, National Cancer Institute, Vilnius, Lithuania,
Abstract
Effect of CDC7 inhibition and MYC degradation on neuroendocrine transformation in the lung and prostate cancer. Org: Memorial Sloan Kettering Cancer Center, New York City, Nykode Therapeutics, New York Oncology Hematology PC, Columbia University Vagelos College of Physicians and Surgeons,
Abstract
Pharmacokinetic analysis of OMO-103 in patient tissues with advanced solid tumors.Org: Peptomyc SL, Biognosys AG,
Abstract
MYC amplification segment-size mutual exclusivity analysis with other oncogenic events in a pan-cancer sequencing cohort.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial.Org: University Hospital Zurich, EORTC - European Organisation for Research and Treatment of Cancer, Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Institute of Neuropathology, Medical Faculty, Heinrich Heine University and University Hospital Düsseldorf, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands,
Abstract
Liquid-biopsy detection of FGFR2 and other actionable rearrangements in GI malignancies.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Englander Institute of Precision Medicine, New York Presbyterian Hospital, Foundation Medicine, Inc., Cambridge, MA, Vanderbilt University Medical Center,
Abstract
Association of C-MYC, MYC target gene, and unfolded protein response (UPR) expression with clinical benefit from the oral aurora kinase A (AURKA) inhibitor, alisertib (A), in combination with paclitaxel (P) compared with P alone in patients (Pts) with HER2-negative metastatic breast cancer (MBC).Org: Integrated Cancer Genomics Division, Translational Genomics Research Institute (TGen North), Phoenix, AZ, Translational Genomics Research Institute, Phoenix, AZ, Translational Genomics Research Institute (Phoenix, AZ),
Abstract
Multi-omic characterization of RCC1 expression and its association with molecular alterations, immune phenotypes, and cancer outcomes.Org: University of California Irvine School of Medicine, Barbara Ann Karmanos Cancer Institute, Lombardi Comprehensive Cancer Center, Caris Life Sciences, Irving, TX, Montefiore Einstein Center for Cancer Care,
Abstract
Effect of MYC-targeting programmable epigenetic mRNA therapeutics on TME and immunotherapy responses.Org: Omega Therapeutics,
Abstract
Multi-factor dynamic analysis of ctDNA and CTC to aid the diagnostic prognosis of patients with metastatic breast cancer (MBC).Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, CTC Core Facility, Lurie Cancer Center,
Abstract
Genomic landscape of multiple myeloma with extramedullary disease: Results from a large patient database.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, University College Dublin Medical School,
Abstract
Initial chemotherapy for locally advanced and metastatic NUT carcinoma: A report from the NUT Carcinoma Registry.Org: Dana-Farber Cancer Institute, Boston, MA, Brigham and Women's Hospital/Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
Cell-free urinary tumor DNA to detect minimal residual disease prior to repeat-transurethral resection of bladder tumor in non-muscle invasive bladder cancer: A prospective study.Org: H. Lee Moffitt Cancer Center and Research Institute, Predicine, Inc., Predicine Inc., Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute,
Abstract
Heterofunctional polymeric degrading chimeras (HYDRAC) for targeted protein degradation.Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University Feinberg School of Medicine,
Abstract
Commercial next generation sequencing in a real-world cohort of patients with metastatic breast cancer.Org: Renaissance School of Medicine at Stony Brook University, Stony Brook University Hospital - Cancer Center,
Abstract
Copy number variation (CNV) calling of MET, MYC, and ERBB2 using PiVAT bioinformatic platform.Org: Shanghai Zhengu Biological Technology Co., Ltd, Pillar Biosciences Inc.,
Abstract
Liquid and tissue profiling of somatic mutational landscape of non-small cell lung cancer from an Indian cohort.Org: Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, NY, India, Adana Acıbadem Hospital, Adana, Turkey, St Bartholomew's Hospital, London, United Kingdom, Fortis Cancer Institute, New Delhi, India, Imperial College London, London, United Kingdom,
Abstract
Biomarker testing and treatment patterns in US patients (pts) with advanced/metastatic non‑small cell lung cancer (NSCLC) harboring MET amplification.Org: West Cancer Center & Research Institute, Merck, ConcertAI,
Abstract
Synergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for the treatment of peripheral T cell lymphoma.Org: Department of Lymphoma, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China, Department of Pathology, Guangdong Provincial People’s Hospital(Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China, Department of Lymphoma, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guandong, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore, Singapore, Singapore,
Abstract
Pan-cancer analysis of tumor mutation burden and other key ICI biomarkers in the Indian cohort.Org: Medanta Medicity, Gurugram, India, Max Super Speciality Hospital, Delhi, India, Max Super Speciality Hospital, Patiala, Punjab, India, Medical College of Wisconsin, Milwaukee, WI, Fortis Cancer Institute, New Delhi, India,